FIXED COMBINATION OF SAXAGLIPTIN AND METFORMIN WITH MODIFIED RELEASE - NEW STEP IN THE IMPROVEMENT OF TREATMENT COMPLIANCE IN TYPE 2 DIABETES MELLITUS


E.V. Biryukova

Department of Endocrinology and Diabetology SBEI HPE MSMSU n.a A.I. Evdokimov of RMPH, Moscow
Currently, growing evidence-based data in the field of diabetology indicate that the optimal components for the realization of the concept of modern fixed combination (FC) includes saxagliptin and metformin MR. New FC of saxagliptin and metformin MR, Kombiglyce Prolong, has a high efficiency, good safety and tolerability profile, and convenient to use. These benefits all allow to improve patients' adherence to the treatment of type 2 diabetes mellitus.

About the Autors


E.V. Biryukova – MD, Prof. at the Department of Endocrinology and Diabetology SBEI HPE MSMSU n.a. A.I. Evdokimov of RMPH; e-mail: lena@obsudim.ru


Similar Articles


Бионика Медиа